Churg-Strauss angiitis.

Area of Science:

• Rheumatology
• Immunology
• Pulmonology

Background:

• Churg-Strauss syndrome (CSA) is an eosinophilic granulomatous inflammation of the respiratory tract with necrotizing vasculitis.
• CSA is often classified as anti-neutrophil antibody (ANCA)-associated systemic vasculitis (AASV) due to overlapping features.
• Recent studies indicate ANCAs are present in only 38% of CSA patients, suggesting heterogeneity.

Purpose of the Study:

• To investigate the distinct clinical, pathological, and pathogenetic features of ANCA-positive versus ANCA-negative CSA.
• To explore potential differences in genetic background and treatment responses between CSA subgroups.

Main Methods:

• Analysis of large patient cohorts to assess ANCA status and its correlation with clinical manifestations.
• Comparison of histological findings and pathogenetic mechanisms in ANCA-positive and ANCA-negative CSA.
• Review of treatment strategies and outcomes for different CSA phenotypes.

Main Results:

• ANCA-positive CSA patients frequently exhibit small-vessel vasculitis (e.g., glomerulonephritis, mononeuritis, purpura).
• ANCA-negative CSA patients are more prone to cardiac and lung involvement, with less frequent histological vasculitis.
• Distinct pathogenetic mechanisms are postulated: ANCA-mediated in positive cases, and eosinophil-driven in negative cases.

Conclusions:

• CSA comprises at least two distinct subsets: ANCA-positive and ANCA-negative, with differing clinical phenotypes and likely distinct pathogenetic pathways.
• Corticosteroids are the primary treatment, with cyclophosphamide for severe or relapsing cases.
• Long-term corticosteroid therapy is often necessary for asthma control in most CSA patients.